title: Selective low-dose valganciclovir for prevention of cytomegalovirus disease following kidney transplantation.
abstract: OBJECTIVE
  To assess the safety of a cytomegalovirus prophylaxis regimen using selective low-dose valganciclovir.
  
  
  METHODS
  Retrospective before-after comparison, including consecutive kidney transplant recipients between 2002 and 2004. Excluded were deaths or graft loss within one month after transplantation. During the first period, universal prophylaxis with oral ganciclovir was used. During the second period, selective prophylaxis with low-dose valganciclovir (450 mg/day) was given to patients at high-risk for CMV disease (D+/R- recipients and patients treated with anti-lymphocyte antibodies) and oral acyclovir to all other patients. We compared the incidence of CMV disease between the two periods.
  
  
  RESULTS
  Two hundred and sixty-four patients underwent kidney transplantation of which 221 were included. The incidence of CMV disease was higher with selective low-dose valganciclovir compared to universal ganciclovir without statistical significance, by intention to treat (4.7% vs. 8.5%, respectively, OR 1.88, 95% CI 0.63-5.60) and among patients adhering to the prophylaxis protocol (3.1% vs. 6.8% respectively, OR 2.85, 95% CI 0.65-12.38). Only late-onset CMV was observed for compliant patients. On multivariate analysis, only recipients' serostatus remained significantly associated with CMV disease (OR 0.22, 95% CI 0.07-0.70).
  
  
  CONCLUSIONS
  Selective low-dose valganciclovir may provide similar protection against CMV when compared to universal oral ganciclovir. Prolongation of prophylaxis beyond 100 days should be explored.
authors.affiliation: Department of Transplantation, Rabin Medical Center, Beilinson Hospital, Tel-Aviv University, Sackler Faculty of Medicine, Tel-Aviv, Israel.
authors.forename: Yafit Partouche
authors.initials: YP
authors.lastname: Avidan
authors.forename: Mical
authors.initials: M
authors.lastname: Paul
authors.forename: Ruth
authors.initials: R
authors.lastname: Rahamimov
authors.forename: Jihad
authors.initials: J
authors.lastname: Bishara
authors.forename: Zmira
authors.initials: Z
authors.lastname: Samra
authors.forename: Scherf
authors.initials: S
authors.lastname: Edna
authors.forename: Eytan
authors.initials: E
authors.lastname: Mor
mesh_terms: D000212:Acyclovir / Q000627:therapeutic use; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D018890:Chemoprevention / Q000379:methods*; D015331:Cohort Studies; D003586:Cytomegalovirus Infections / Q000517:prevention & control*; D005260:Female; D015774:Ganciclovir / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D016030:Kidney Transplantation / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D000077562:Valganciclovir
chemical_list: D000998:Antiviral Agents; D000077562:Valganciclovir; D015774:Ganciclovir; D000212:Acyclovir